Pill vs. needle: can Lower-Dose blood thinners protect blood cancer patients from deadly clots?
NCT ID NCT07270263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two types of blood thinners taken as pills (apixaban and rivaroxaban) against a standard daily injection (enoxaparin) to prevent dangerous blood clots in people with blood cancers like lymphoma, leukemia, and multiple myeloma. About 100 participants will be randomly assigned to one of the three treatments for at least six months. The goal is to see which option is safest and most effective at preventing clots while minimizing bleeding risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apixaban, rivaroxaban, and enoxaparin (low-molecular-weight heparin)
What this could lead to
If successful, this could offer blood cancer patients a safer, more convenient pill option to prevent blood clots, reducing the need for daily injections.
What could go wrong
This is a small, early-phase study with only 100 participants, so results may not apply to all patients. There is a risk of bleeding with any blood thinner.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Department of Haematology & Transplantology
RECRUITINGGdansk, Pomeranian Voivodeship, 80-152, Poland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Contact